Oslo based Biopharma Bionor has a Phase I results for a HIV vaccine. The vaccine infusion rendered viral presence in 88% of patients undetectable after combination treatments with Celgene‘s enzyme inhibitor, Istodax and standard retroviral drugs.
The positive results from the clinical trial REDUC Part B were published in the high impact journal The Lancet HIV.
The Norwegian’s proprietary vaccine works as a therapy in conjunction with other drugs to ‘work towards a functional HIV cure’.
The vaccine (Vacc-4x) was tested in a Phase Ib/2a trial in combination with Celgene’s Istodax (romidepsin), well known cancer specific cytotoxic protein. Adults who were infected with HIV and already receiving cART (combination anti-retroviral therapy) for over a year were recruited for the trial at the Aarhus University hospital in Denmark.
Vacc-4x is designed to induce CD4+ and CD8+ T-cell responses, to stimulate the immune system to remove HIV-infected cells.